Roivant Sciences Ltd.
ROIV
Clasificación en acciones
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Precio por acción
$33.73
Última sincronización: 2026-07-31
Capitalización bursátil
$24.37B
Cambio (1 día)
-2.28%
Cambio (1 año)
90.15%
País
GB
Comercio Roivant Sciences Ltd. (ROIV)
Categoría
Healthcare
Ratio P/B de Roivant Sciences Ltd. (ROIV)
Ratio P/B al October 2026 TTM: 5.73
Según los informes financieros más recientes y el precio de las acciones de Roivant Sciences Ltd., el ratio P/B actual (TTM) es 5.73. Al final de 2024, el ratio P/B era 1.37.
Historial del ratio P/B de Roivant Sciences Ltd. desde 2020 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 5.73 | 267.12% |
| 2025 | 1.56 | 14.08% |
| 2024 | 1.37 | -69.88% |
| 2023 | 4.54 | 127.54% |
| 2022 | 2.00 | -46.40% |
| 2021 | 3.73 | 6.30% |
| 2020 | 3.50 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | 9.15% |
US
|
|
| 13.2547 | 131.44% |
US
|
|
| 4.208 | -26.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 7.95% |
NL
|
